Clinical usefulness of geriatric assessment in elderly patients with unresectable hepatocellular carcinoma receiving sorafenib or lenvatinib therapy
Abstract Background Therapeutic strategies for unresectable hepatocellular carcinoma (u‐HCC) in geriatric patients are important for real‐world practice. However, there remain no established biomarkers or therapeutic strategies regarding the best second‐line agent after atezolizumab plus bevacizumab...
| Main Authors: | Shuhei Sekiguchi, Kaoru Tsuchiya, Yutaka Yasui, Kento Inada, Sakura Kirino, Koji Yamashita, Yuka Hayakawa, Leona Osawa, Mayu Higuchi, Kenta Takaura, Chiaki Maeyashiki, Shun Kaneko, Nobuharu Tamaki, Hiroyuki Nakanishi, Jun Itakura, Yuka Takahashi, Yasuhiro Asahina, Ryuichi Okamoto, Masayuki Kurosaki, Namiki Izumi |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Wiley
2022-11-01
|
| Series: | Cancer Reports |
| Subjects: | |
| Online Access: | https://doi.org/10.1002/cnr2.1613 |
Similar Items
-
Real-Life Clinical Data of Lenvatinib versus Sorafenib for Unresectable Hepatocellular Carcinoma in Italy
by: Burgio V, et al.
Published: (2021-12-01) -
Conversion surgery for hepatocellular carcinoma after tyrosine kinase inhibitor treatment
by: Shun Kaneko, et al.
Published: (2022-05-01) -
Clinical impact of lenvatinib in patients with unresectable hepatocellular carcinoma who received sorafenib
by: Yen-Yang Chen, et al.
Published: (2020-11-01) -
Pharmacokinetic Interactions between Canagliflozin and Sorafenib or Lenvatinib in Rats
by: Yanjun Cui, et al.
Published: (2022-08-01) -
Efficacy of lenvatinib versus sorafenib in the primary treatment of advanced hepatocellular carcinoma: A meta‐analysis
by: Vikash Jaiswal, et al.
Published: (2023-12-01)